{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-336841","form_type":"8-K","ticker":"MBX","cik":"0001776111","company_name":"MBX Biosciences, Inc.","filed_at":"2026-08-06T12:03:59+00:00","discovered_at":"2026-08-06T12:05:14.508599+00:00","generated_at":"2026-08-06T12:05:30.744818+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MBX Biosciences Q2 net loss $37.1M; cash $418.6M; canvuparatide Phase 3 recruiting; MBX 4291 7% weight loss","bullets":["Net loss of $37.1M for Q2 2026 vs $19.4M in Q2 2025; R&D expenses rose to $31.0M from $17.7M.","Cash, cash equivalents and marketable securities of $418.6M as of June 30, 2026; expected to fund operations into 2029.","Phase 3 oPTimize trial of once-weekly canvuparatide in hypoparathyroidism now recruiting; sites activated.","MBX 4291 Phase 1 data: 7% mean weight loss at 8 weeks in first MAD cohort; 12-week MAD data on track for Q4 2026.","Steve Hoerter appointed Chairman and CEO; John Smither appointed CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-336841","json":"https://secwatch.observer/filing/0001193125-26-336841.json","markdown":"https://secwatch.observer/filing/0001193125-26-336841.md","text":"https://secwatch.observer/filing/0001193125-26-336841.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526336841/0001193125-26-336841-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526336841/mbx-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:05:30.744818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}